Lithium Ion

Lithium Ion

SCHEMBL209972

Cc1ccc(NC(=O)C(=O)[O-])s1.[Li+]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.53
RAB9A P51151 4/20 0.53
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NFKB1 P19838 2/20 0.53
TP53 P04637 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RAF1 P04049 1/20 0.39
DAO P14920 1/20 0.38
ATF1 P18846 1/20 0.38
KMT2A Q03164 7/20 0.35
MEN1 O00255 5/20 0.35
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705561 0.85 NFKB1 (0.61) NPC1RAB9AMAPTSMN1; SMN2NFKB1
SCHEMBL209971 0.83 NFKB1 (0.59) NPC1RAB9AMAPTSMN1; SMN2NFKB1
SCHEMBL1005754 0.78 NPC1 (0.67) NPC1RAB9AMAPTSMN1; SMN2NFKB1
Lithium Ion SCHEMBL210530 0.78 GAA (0.39) NPC1RAB9AMAPTSMN1; SMN2NFKB1
SCHEMBL208477 0.78 NPC1 (0.53) NPC1RAB9AMAPTSMN1; SMN2NFKB1
SCHEMBL14584377 0.76 HSD17B10 (0.75) NPC1RAB9AMAPTSMN1; SMN2NFKB1
SCHEMBL206754 0.68 NFKB1 (0.50) NPC1RAB9AMAPTSMN1; SMN2NFKB1
SCHEMBL11461143 0.66 MAPT (0.59) NPC1RAB9AMAPTSMN1; SMN2NFKB1
Lithium Ion SCHEMBL6561676 0.66 DAO (0.61) NPC1RAB9AMAPTSMN1; SMN2TP53
SCHEMBL12841742 0.65 NFKB1 (0.47) NPC1RAB9AMAPTSMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
CN-101163700-A Triamine derivative DAIICHI SEIYAKU CO (JP) 2008-04-16 CN disclosed
EP-1864982-A1 TRIAMINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239857-A1 TRIAMINE DERIVATIVE F2, F12, F3 NPC1 3007/4885RAB9A 4576/4885MAPT 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.